highly significantp=0.001
Conversely, trials achieving a moderate to large SBP reduction (≥2 mmHg) demonstrated a significant 22% relative risk reduction in stroke (RR: 0.78; 95% CI: 0.71-0.85) with a highly significant test of subgroup difference (p=0.001).